Waldencast (WALD) Company Overview

LONDON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, announced upcoming earnings release, conference call and webcast information for the fourth quarter and full fiscal year 2024 and first, second, and third quarters of fiscal year 2025. The webcasts will be available on the Investor Relations page on the company's website at https://ir.waldencast.com/ approximately 2 weeks prior to the events.

LONDON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, today announced its participation in the 2025 International Master Course on Aging Science (IMCAS) World Congress, which will be held in Paris from January 30, 2025 to February 1, 2025.

WHITE PLAINS, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that the Company will participate in investor meetings and host a presentation at the ICR Conference 2025 being held at The Grande Lakes Orlando in Orlando, Florida on January 13, 2025.

Waldencast plc. (NASDAQ:WALD ) Q3 2024 Earnings Conference Call November 21, 2024 8:30 AM ET Company Participants Allison Malkin - Investor Relations, ICR Michel Brousset - Founder and Chief Executive Officer Manuel Manfredi - Chief Financial Officer Conference Call Participants Jonna Kim - TD Cowen Dana Telsey - Telsey Advisory Group Sydney Wagner - Jefferies Susan Anderson - Canaccord Genuity Linda Bolton Weiser - D.A.

$70.2 million of Net Revenue Q3 2024+34.6% Comparable Net Revenue GrowthBoth brands accelerating from Q2 2024+45.5% Obagi Medical and +23.5% Milk Makeup vs Q3 2023Adjusted EBITDA of $11.4 million, up +134.0% vs Q3 2023

NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, announced today that Hind Sebti, Kelly Brookie and Roberto Thompson have been appointed to its board of Directors (the “Board”), effective September 26, 2024. These executives bring extensive professional experience further enhancing the breadth of talent and expertise possessed by the Board. Ms. Brookie will replace Sarah Brown who has informed the Board of her intention to not renew her mandate ahead of the Company's Annual General Meeting. The Company also announced that its Annual General Meeting is scheduled for October 28, 2024 during which the Company's shareholders will be asked to vote on the renewal of Class I and Class II directors. Following this announcement, the Board will include 11 members, each of whom possesses significant expertise, particularly in the beauty, financial and consumer products sectors.

These New Products are the Latest Innovation to Obagi's ELASTIDERM® Collection These New Products are the Latest Innovation to Obagi's ELASTIDERM® Collection

Waldencast posted Q2 sales that came in far above the market's expectations. Comparable sales growth accelerated significantly on a sequential quarterly basis.

$63.3 million of Net Revenue Q2 2024 +25.7% net revenue Comparable Growth: +30.9% Obagi Medical and +20.0% Milk Makeup vs Q2 2023 Adjusted EBITDA of $6.3 million, up +64.5% vs Q2 2023